| General Information | |
|---|---|
| ZINC ID | ZINC000042850932 |
| Molecular Weight (Da) | 413 |
| SMILES | CCCCCCCCCCCC[P@](=O)(Oc1ccc([N+](=O)[O-])cc1)OC(C)C |
| Molecular Formula | C21N1O5P1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 113.464 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 16 |
| Heavy Atoms | 28 |
| LogP | 7.044 |
| Activity (Ki) in nM | 12.0226 |
| Polar Surface Area (PSA) | 88.48 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.691 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.71 |
| Ilogp | 4.81 |
| Xlogp3 | 7.5 |
| Wlogp | 7.51 |
| Mlogp | 3.83 |
| Silicos-it log p | 3.76 |
| Consensus log p | 5.48 |
| Esol log s | -6.23 |
| Esol solubility (mg/ml) | 0.000243 |
| Esol solubility (mol/l) | 0.00000058 |
| Esol class | Poorly sol |
| Ali log s | -9.25 |
| Ali solubility (mg/ml) | 0.00000023 |
| Ali solubility (mol/l) | 5.65E-10 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.85 |
| Silicos-it solubility (mg/ml) | 0.0000587 |
| Silicos-it solubility (mol/l) | 0.00000014 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.5 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 1 |
| Egan number of violations | 1 |
| Muegge number of violations | 2 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 3 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 5.23 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.192 |
| Logd | 4.762 |
| Logp | 6.559 |
| F (20%) | 0.003 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 99.64% |
| Vdss | 1.326 |
| Fu | 0.84% |
| Cyp1a2-inh | 0.17 |
| Cyp1a2-sub | 0.216 |
| Cyp2c19-inh | 0.74 |
| Cyp2c19-sub | 0.218 |
| Cl | 1.212 |
| T12 | 0.034 |
| H-ht | 0.049 |
| Dili | 0.825 |
| Roa | 0.107 |
| Fdamdd | 0.206 |
| Skinsen | 0.958 |
| Ec | 0.595 |
| Ei | 0.927 |
| Respiratory | 0.903 |
| Bcf | 1.814 |
| Igc50 | 5.609 |
| Lc50 | 6.392 |
| Lc50dm | 6.392 |
| Nr-ar | 0.032 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.938 |
| Nr-aromatase | 0.991 |
| Nr-er | 0.754 |
| Nr-er-lbd | 0.546 |
| Nr-ppar-gamma | 0.395 |
| Sr-are | 0.662 |
| Sr-atad5 | 0.002 |
| Sr-hse | 0.02 |
| Sr-mmp | 0.931 |
| Sr-p53 | 0.058 |
| Vol | 427.445 |
| Dense | 0.967 |
| Flex | 2 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 5 |
| Surechembl | 1 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.121 |
| Synth | 2.912 |
| Fsp3 | 0.714 |
| Mce-18 | 20 |
| Natural product-likeness | -0.38 |
| Alarm nmr | 2 |
| Bms | 2 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |